Health and environment

The global prefilled syringes market size is expected to reach a value of USD 22.5 billion by 2025, according to a new report by Grand View Research, Inc. The market is estimated to expand at a CAGR of 11.2% during the forecast years. Growing usage of prefilled syringes and technological advancements in auto-injectors are the key factors driving the market. Prefilled syringes are rapidly replacing traditional syringe-vial combinations due to advantages offered

The global continuous peripheral nerve block (cPNB) catheters market is expected to reach USD 292.8 million by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 6.2% during the forecast period. Growing orthopedic surgery volumes resulting from rising prevalence of osteoarthritis and increasing preference for ambulatory surgical centers are the key growth stimulants for the cPNB catheters market. According to the Healthcare Cost and Utilization

Owen Mumford Launches New HIV Rapid Testing to European Markets

Owen Mumford, a company with a reputation for innovative products, has announced that it has acquired exclusive rights to sell and distribute the rapid diagnostic HIV test, Simplitude™ Pro HIV across Europe. Senior Product Manager, Tania MacKenzie says, ‘We are delighted to be introducing the product to the European market for the first time at AIDS2018 in Amsterdam. ‘We believe that Simplitude™ Pro HIV meets the need for a reliable

Orthodontic Supplies Market Worth Over $7 Billion by 2024: Global Market Insights, Inc.

World Orthodontic Supplies Market is projected to cross USD 7 billion by 2024; according to a new research study published by Global Market Insights, Inc. Increasing incidence of malocclusion in children and adults will drive industry growth during the forecast period. Currently around 60% to 75% of the total global population is suffering from malocclusion or misaligned teeth. Rise in need for orthodontic treatment for malocclusions and other different orthodontic

OWC Pharmaceutical Research Corp. Completes First Part of Cannabis-Based Ointment Safety Study

OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, yesterday announced a successful completion of the first part of its Phase I, placebo controlled, maximal dose study (the ‘Psoriasis Study’) to determine the safety and tolerability of topical ointment containing medical grade cannabis (the ‘Topical Ointment’) in healthy volunteers. The study is being performed by Professor Aviv Barzilai, Director

A Key to the Cage: Opening the Living Membrane Gate

Research led by Oleg Batishchev and conducted jointly by scientists from NUST MISIS, the A.N. Frumkin Institute of Physical Chemistry & Electrochemistry (Russian Academy of Sciences), and the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry The lipid membrane of a cell is the basis of every living organism. This membrane is an amazingly intuitive ‘fence’ through which the cell communicates with the body, eats, protects against foreign invaders, and controls the flow of

Investments Into Cannabis Companies are Expected to Increase News Commentary According to a research report provided by Marijuana Business Daily, cannabis retail sales continue to grow year-over-year as new markets emerge and more states legalize medical and recreational cannabis. Sales in 2018 are expected to surge by approximately 50% compared to last year, meaning sales value is on track to reach USD 8 Billion – USD 10 Billion by the end of this year. The research also

European Hematology Association: Update on bb2121, a Promising Therapy for Patients with Heavily Pre-treated Relapsed/Refractory Multiple Myeloma

The anti-BCMA CAR T cell therapy bb2121 has demonstrated substantial activity in heavily pre-treated patients with multiple myeloma (MM). Updated results from 43 patients after five more months of follow-up show that bb2121 remains generally well-tolerated while inducing deep and durable responses in patients with advanced MM. The median PFS among 18 patients treated with active doses in the dose escalation cohort was 11.8 months and a 96% ORR was

Immunovia Announces its Intent to Carry out a Directed Share Issue

Immunovia AB (publ) (‘Immunovia’ or the ‘Company’) today announces its intention to execute a directed share issue to Swedish and international qualified and/or institutional investors (the ‘Share Issue’). The contemplated Share Issue will be carried out under the authorization received from the annual general meeting on May 3, 2018 and may entail an issue of a maximum number of shares corresponding to a maximum of 20 percent of the number

New Tech Could Transform the $60B Marijuana Industry

FN Media Group Presents News Commentary  The back pain was killing him – clearly, the time had come to seek treatment. But instead of prescription drugs, Todd Guillion opted for medical marijuana. Why not? The Orange County, California native figured it had to be safer than pharmaceuticals. But shortly after beginning his cannabis regimen, he began suffering terrible numbness in his arms, hands and feet. Mentioned in today”s commentary